The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: A randomized, double-blind, clinical trial

Trials

Volumn 19, Issue 1, 2018, Pages

  Ahmadi, Jamshid ^a   Jahromi, Mina Sefidfard ^a   Ehsaei, Zahra ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Buprenorphine; Opioid dependence; Suicidal ideation

Indexed keywords

BUPRENORPHINE; ANTIDEPRESSANT AGENT; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; BECK SCALE FOR SUICIDAL IDEATION; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DSM-5; HUMAN; MAJOR DEPRESSION; MALE; OPIATE ADDICTION; PROBABILITY; PSYCHOLOGICAL RATING SCALE; PSYCHOMETRY; SCORING SYSTEM; SINGLE DRUG DOSE; STRUCTURED INTERVIEW; SUICIDAL IDEATION; TREATMENT OUTCOME; DOUBLE BLIND PROCEDURE; IRAN; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; SUBLINGUAL DRUG ADMINISTRATION; TIME FACTOR; WITHDRAWAL SYNDROME;

ADMINISTRATION, SUBLINGUAL; ADULT; ANALGESICS, OPIOID; ANTIDEPRESSIVE AGENTS; BUPRENORPHINE; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; HUMANS; IRAN; MALE; OPIOID-RELATED DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME; SUICIDAL IDEATION; TIME FACTORS; TREATMENT OUTCOME;

EID: 85052522104     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-018-2843-9     Document Type: Article

References (41)

1. Centers for Disease Control and Prevention. Suicide Among Adults Aged 35-64 Years - United States, 1999-2010. MMWR Morb Mortal Wkly Rep. 2013;62(17):5.
2. Olfson M, et al. Emergency treatment of young people following deliberate self-harm. Arch Gen Psychiatry. 2005;62(10):1122-8.
3. Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol. 2011;14(8):1127-31.
4. Cipriani A, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646.
5. George MS, et al. A two-site pilot randomized 3 day trial of high dose left prefrontal repetitive transcranial magnetic stimulation (rTMS) for suicidal inpatients. Brain Stimul. 2014;7(3):421-31.
6. Fink M, Kellner CH, McCall WV. The role of ECT in suicide prevention. J ECT. 2014;30(1):5-9.
7. Striebel JM, Kalapatapu RK. The anti-suicidal potential of buprenorphine: a case report. Int J Psychiatry Med. 2014;47(2):169-74.
8. Yovell Y, et al. Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial. Am J Psychiatry. 2016;173(5):491-8.
9. Greenwald M, et al. Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiatry. 2007;61(1):101-10.
10. Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: rescheduling of buprenorphine from schedule V to schedule III. Final rule. Fed Regist. 2002;67(194):62354-70.
11. Ahmadi J. The effect of buprenorphine on the reduction of cannabis and heroin craving and suicidal thoughts: a new finding. iMedPub. 2016;1(2:7):3.
12. Ahmadi J. Fast treatment of methamphetamine related anxiety and depressive disorders: a novel approach. J Addict Med Ther Sci. 1(2):044-6. https://doi.org/10.17352/2455-3484.000011.
13. Ahmadi J. Instant detoxification of heroin with high dose of buprenorphine. J Addict Prev. 2016;4(1):3.
14. Gracer R. The buprenorphine effect on depression. The National Alliance of Advocates for Buprenorphine Treatment (NAABT) Vol 3, No 2, Feb. 2007 newsletter.
15. Sadock B, Sadock V, Ruiz P, editors. Kaplan & Sadock's Synopsis of Psychiatry. Philadelphia: Lippincott Williams & Wilkins; 2015.
16. Ahmadi J, Sefidfard Jahromi M. Ultrarapid Influence of Buprenorphine on Major Depression in Opioid-Dependent Patients: A Double Blind, Randomized Clinical Trial. Subst Use Misuse. 2017;17:1-4.
17. Ipser JC, Terburg D, Syal S, Phillips N, Solms M, Panksepp J, van Honk J. Reduced fear-recognition sensitivity following acute buprenorphine administration in healthy volunteers. Psychoneuroendocrinology. 2013;38(1):166-70.
18. Maremmani AGI, Rovai L, Pani PP, Pacini M, Lamanna F, Rugani F, Maremmani I. Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts? Ann General Psychiatry. 2011;10(1):1.
19. Falcon E, Maier K, Robinson SA, Hill-Smith TE, Lucki I. Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice. Psychopharmacology. 2015;232(5):907-15.
20. Beck AT, Steer RA, Ranieri WF. Scale for suicide ideation: psychometric properties of a self-report version. J Clin Psychol. 1988;44(4):499-505.
21. Soyka M. New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone. Subst Abuse Rehabil. 2015;6:1-14. https://doi.org/10.2147/SAR.S45585.
22. Mintzer MZ. Effects of opioid pharmacotherapy on psychomotor and cognitive performance: a review of human laboratory studies of methadone and buprenorphine. Heroin Addict Relat Clin Prob. 2007;9:5-24.
23. Darke S, Ross J. Polydrug dependence and psychiatric comorbidity among heroin injectors. Drug Alcohol Depend. 1997;48:135-41.
24. Ross J, Teesson M, Darke S, et al. The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev. 2005;24:411-8.
25. Rounsaville BJ, Weissman MM, Crits-Christoph K, Wilber C, Kleber H. Diagnosis and symptoms of depression in opiate addicts. Course and relationship to treatment outcome. Arch Gen Psychiatry. 1982;39:151-6.
26. Savant JD, Barry DT, Cutter CJ, et al. Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment. Drug Alcohol Depend. 2013;127:243-7.
27. Schäfer I, Fischer M, Reimer J, Karow A, Haasen C. Significance of psychiatric comorbidity for the outcome of maintenance treatment - a review of the literature. Ment Health Subst Use. 2011;4:62-71.
28. Strain EC. Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients. Clin J Pain. 2002;18:S14-27.
29. Merikangas KR, Mehta RL, Molnar BE, et al. Comorbidity of substance use disorders with mood and anxiety disorders: results of the International Consortium in Psychiatric Epidemiology. Addict Behav. 1998;23:893-907.
30. Merikangas KR, Zhang H, Avenevoli S, Acharyya S, Neuenschwander M, Angst J. Longitudinal trajectories of depression and anxiety in a prospective community study: the Zurich Cohort Study. Arch Gen Psychiatry. 2003;60:993-1000.
31. Moggi F. Etiological models on the relationship of mental disorders and substance use disorders. Suchtmed. 2013;15:327-33. German
32. Soyka M. Affective and anxiety disorders and drug addiction. Suchtmed, German. 2013;15:341-8.
33. Darke S, Mills K, Teesson M, Ross J, Williamson A, Havard A. Patterns of major depression and drug-related problems amongst heroin users across 36 months. Psychiatry Res. 2009;166:7-14.
34. Torrens M, Martínez-Sanvisens D, Martínez-Riera R, Bulbena A, Szerman N, Ruiz P. Dual diagnosis: focusing on depression and recommendations for treatment of opioid dependence. Addict Disord Treat. 2011;10:50-9.
35. Rothman RB, Gorelick DA, Heishman SJ, et al. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence. J Subst Abus Treat. 2000;18:277-81.
36. Bodkin JA, Zornberg GL, Lukas SE, Cole JO. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995;15:49-57.
37. Emrich HM, Vogt P, Herz A, Kissling W. Antidepressant effects of buprenorphine. Lancet. 1982;2:709.
38. Gerra G, Leonardi C, D'Amore A, et al. Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: a retrospective study. Prog Neuro-Psychopharmacol Biol Psychiatry. 2006;30:265-72.
39. Schmauss C, Yassouridis A, Emrich HM. Antipsychotic effect of buprenorphine in schizophrenia. Am J Psychiatry. 1987;144:1340-2.
40. Wee S, Koob GF. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology. 2010;210:121-35.
41. Todtenkopf MS, Marcus JF, Portoghese PS, Carlezon WA Jr. Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology. 2004;172:463-70.